Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:12:52.890Z.
Calculation as of: 2026-10-06T18:12:52.890Z.
Quote observation: 2026-10-06T18:10:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 15f4d798ccf4875796eb71b515450313e327808a34ea0284d87d2ac67ba5f97e
PE RATIO
N/A
Market Cap
$7.13M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Longeveron Inc. (LGVN) | $7.21M | N/A | N/A | N/A | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.25M | N/A | N/A | N/A | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.13M | N/A | N/A | N/A | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.12M | N/A | N/A | N/A | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.08M | N/A | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.06M | N/A | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $7.00M | N/A | 4.85 | 10.48 | 10.48 |
| Skye Bioscience, Inc. (SKYE)vs › | $7.53M | N/A | 0.69 | 0.69 | 0.69 |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.74M | N/A | N/A | N/A | N/A |
| Exicure, Inc. (XCUR)vs › | $6.82M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$2.37
Forward EPS (Est.)
$-7.75
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
